YCM
VRDN icon

Yiheng Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Yiheng Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.36M Buy
400,464
+191,729
+92% +$3.09M 2.53% 13
2026
Q1 		$4.08M Hold
208,735
– – 1.77% 16
2025
Q4 		$6.5M Sell
208,735
-291,526
-58% -$8M 1.31% 13
2025
Q3 		$10.8M Hold
500,261
– – 1.59% 13
2025
Q2 		$6.99M Hold
500,261
– – 0.63% 15
2025
Q1 		$6.74M Sell
500,261
-250,000
-33% -$4.26M 0.63% 13
2024
Q4 		$14.4M Sell
750,261
-97,630
-12% -$2.12M 0.55% 14
2024
Q3 		$19.3M Sell
847,891
-100,239
-11% -$1.64M 0.99% 11
2024
Q2 		$12.3M Hold
948,130
– – 0.99% 17
2024
Q1 		$16.6M Sell
948,130
-280,404
-23% -$5.44M 0.92% 15
2023
Q4 		$26.8M Hold
1,228,534
– – 1.54% 12
2023
Q3 		$18.8M Hold
1,228,534
– – 0.96% 17
2023
Q2 		$29.2M Hold
1,228,534
– – 1.58% 16
2023
Q1 		$31.3M Buy
1,228,534
+265,278
+28% +$8.51M 1.24% 16
2022
Q4 		$28.1M Buy
963,256
+590,205
+158% +$13.6M 1.25% 17
2022
Q3 		$7.65M Buy
+373,051
New +$6.71M 0.47% 23

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Yiheng Capital Management's VRDN Position: Q2 2026 in Review

Yiheng Capital Management increased its Viridian Therapeutics (VRDN) stake by 92% in Q2 2026, buying an estimated $3.09M and bringing the position to 400,464 shares worth $7.36M. The position accounts for 2.53% of the portfolio, ranked #13.

Yiheng Capital Management first reported a position in VRDN in Q3 2022 and has held it in 16 quarters since. The position peaked at $31.3M in Q1 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Yiheng Capital Management held 400,464 shares of Viridian Therapeutics worth $7.36M as of Q2 2026.
  • Yiheng Capital Management bought 191,729 Viridian Therapeutics shares in Q2 2026, an estimated $3.09M.
  • Viridian Therapeutics made up 2.53% of Yiheng Capital Management's portfolio in Q2 2026, its #13 holding.
  • Yiheng Capital Management first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Yiheng Capital Management's Viridian Therapeutics position peaked at $31.3M in Q1 2023.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Yiheng Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.